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Momordica  charantia  plant  is consumed  as  a foodstuff  in  some  south  Asian  curries  while  its  extract  prepa-
rations  have  been  traditionally  used  for  lowering  blood  glucose  levels  in patients  with  diabetes  mellitus.
Nutritional  Health  Institute  Laboratories  (NHIL),  LLC,  Florida  informed  that  it patented  a new  plant  McB,
as an interhybrid  of  three  plants  of Momordica  genus.  The  objective  of  the  present  study  was  to investi-
gate  potential  adverse  effects,  if  any,  of  McB-E60  (extract  of  a Momordica  sp.)  in rats  following  subchronic
administration.  Sprague-Dawley  rats (10/sex/group)  were  administered  via  oral  gavage  0 (control),  250,
500  and  1000 mg/kg  body  weight  (bw)/day  of  McB-E60  for 90 days.  Additional  28-day  recovery  groups
were  maintained  at control  and  high  dose  levels.  No  mortality  or  signiﬁcant  and  adverse  changes  in
clinical  signs,  neurological  signs,  body  weight  gain  or feed  intake  were  noted.  No  toxicologically  signif-
icant  changes  in  hematology,  clinical  chemistry,  urinalysis  and  organ  weights  were  noted.  Gross  and
microscopic  pathology  examinations  did  not  reveal  treatment-related  abnormalities.  Any  changes  noted
were incidental  and  within  historical  control  ranges.  Based  on the  results  of this  study,  the  No-Observed-
Effect  Level  (NOEL)  for McB-E60  (extract  of a Momordica  sp.)  was determined  as greater  than  1000  mg/kg
bw/day,  the  highest  dose  tested.
© 2016  Nutritional  Health  Institute  Laboratories  LLC.  Published  by  Elsevier  Ireland  Ltd.  This  is an  open
he  CCaccess  article  under  t
. Introduction
Approximately 40% of Americans use complementary and alter-
ative medicine (CAM) for health promotion and the treatment of
llness [10]. Of these users, 2 and 3 million speciﬁcally use CAM
o lower blood sugar levels and to treat various stages of diabetes,
espite limited studies of their safety and efﬁcacy [2]. An estimated
9 million adult Americans have pre-diabetes, a condition that is
reventable and treatable if recognized early [1]. Individuals with
re-diabetes have glycated hemoglobin (HgA1c) and blood sugar
evels that are below the clinical threshold to be classiﬁed as type 2
iabetes but are higher than normal [4]. Pre-diabetics, if not treated
ppropriately, are at risk for becoming diabetic and developing
ardiovascular disease [9,13].
Abbreviations: ALKP, alkaline phosphatase; ALT, alanine aminotransferase; AST,
spartate aminotransferase; BUN, blood urea nitrogen; FDA, food and drug admin-
stration; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume;
OEL, no-observed-effect level; OECD, organization for economic co-operation and
evelopment.
∗ Corresponding author at: INTOX Private Limited, 375 Urawade, Tal. Mulshi, Dist.
une − 412 115, Maharashtra, India.
E-mail addresses: nsdeshmukh@intoxlab.com,
arendra deshmukh@hotmail.com
ttp://dx.doi.org/10.1016/j.toxrep.2016.05.006
214-7500/© 2016 Nutritional Health Institute Laboratories LLC. Published by Elsevier 
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Momordica charantia, also known as Bitter melon, is a widely
used traditional remedy for hyperglycemia. A member of the cucer-
bitaceae family, Bitter melon is a perennial climber characterized
by warty-fruit like gourds or cucumbers. It is a commonly con-
sumed vegetable found throughout the sub-tropical world (China,
India, Thailand, East Africa, The Caribbean, Central and South Amer-
ica) and is known by various names, such as balsam pear, bitter
gourd, cundeamor, goo-fah, karela, etc [11,6]. The fruit, as well
as the whole plant is believed to possess anti-diabetic, anti-viral,
anti-bacterial and anticancer properties and has been scientiﬁcally
evaluated in the recent past [5]. The immature fruits of M.  charan-
tia can be prepared in many ways for food uses. Fruits, ﬂowers,
and young shoots are also used as a ﬂavoring. The young shoots
and leaves are sometimes cooked and eaten as leafy vegetables
[7]. In recent years, processed bitter gourd in the form of capsules
or tablets is commonly marketed as a dietary supplement under
the brand names Gourdin, Karela, and Glucobetic in Canada, India,
United Kingdom, the United States, and many Asian countries [7].
In several in vitro and animal model studies, the plant has
been investigated for its mechanism of action as an anti-diabetic.
Over 228 different compounds with possible medicinal proper-
ties, acting alone or in combination, have been isolated from bitter
melon fruit, seeds, leaves, stems, pericaps, endosperm, callus tis-
sues, and cotyledons [3]. Of the various compounds identiﬁed,
Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Table 1
Description and speciﬁcations of McB-E60 (extract of a Momordica sp.).
Product Description
It is a green clear crystalline liquid extract obtained from a new interhybrid of
three plants of Momordica genus
Parameter Results Method
pH 4.12 USP 791
Gentisic Acid <0.01 ppm Internal (HPLC) Method—KK123
Stigmasterol 0.01% (w/w) Internal (GC) Method—KK329
Total sterols 0.0115% (w/w) Internal (GC) Method—KK329
Dry Ashing <1% –
Residual ethanol 48,000 mg/kg USP/NF 467
Total dietary ﬁbre <0.2% (w/w)
Combustion proteins 1.41% AOAC 990.03, 992.15
Heavy metals
Total heavy metals <0.02 ppm
Cadmium <0.002 ppm AOAC 993.14 Mod.
Lead <0.007 ppm AOAC 993.14 Mod.
Mercury <0.004 ppm AOAC 993.14 Mod.
Arsenic <0.007 ppm AOAC 993.14 Mod.
Microbiological assays
Yeast and moulds <10 (est) CFU/g BAM Chapt. 18
Total Aerobic plate count<10 (est) CFU/g AOAC 990.12
Total coliform <10 (est) CFU/g AOAC 991.14
Escherichia coli <10 (est) CFU/g AOAC 991.14
Staphylococcus aureus <10 (est) CFU/g AOAC 2003.07
Salmonella Not Detected per 25 gAOAC 2003.09
Other Contaminants
Apart from above, the sample was  analysed for several
pesticides—organochlorine, pyrethroids, organonitrogen,
organophosphorous, carbamates and for aﬂatoxins, to ensure that it
was  free from undesired levels of the same.
Ref. (except for product description and ash content): Certiﬁcate of analysis—AR-
15-KK-000614-01 dated January 12, 2015, of Euroﬁns Scientiﬁc, Inc., Supplement82 N.S. Deshmukh / Toxicolo
haratin, polypeptide-p, vicine, momordin, and similar derivatives
ave been claimed to improve glycemic control [3]. The available
nformation indicates that bitter melon has been traditionally used
o treat high blood sugar and diabetes. For over 70 years, studies
ave appeared sporadically in the literature indicating the beneﬁt
f bitter melon in lowering blood sugar. In human studies, bit-
er melon juice, fruit, and dried powder have been investigated
or hypoglycemic effect. Only a few randomized controlled trials
f bitter melon have been conducted. In a prospective, random-
zed, double-blinded and placebo-controlled trial of bitter melon,
 statistically signiﬁcant decrease in HbA1c levels after 4 months
f intervention, compared with a referent group receiving reﬁned
oybean oil was noted [14].
In an attempt to further develop improved varieties of
omordica species for use in humans to control blood sugar, sev-
ral investigators have attempted to develop new varieties and
trains of Momordica by inter species hybridization. NHIL has
eveloped and patented a new plant variety which is a plant
rown from seeds derived from a new interhybrid of three plants
f Momordica genus. This newly derived plant hybrid of genus
omordica (McB interhybrid) has been stabilized and asexually
eproduced. The McB  interhybrid has been described as an interhy-
rid derived from a cross of Momordica charantia, commonly known
s bitter melon, Momordica balsamina,  and a previously unnamed
omordica species native to Ecuador. In particular the McB  inter-
ybrid is a tetra-cross pollinated hybrid plant of the Momordica
pecies. The extract (McB-E60) evaluated in the present study is
erived exclusively from the leaves, petioles and stem (the fruits,
ower and roots are not included) of the new interhybrid plant.
Given the potential use of bitter melon (M.  charantia)  as a dietary
upplement in possible support for maintaining blood glucose, the
bjective of this study was to investigate the long-term repeat dose
oxicity of McB-E60 (extract of a Momordica sp.). In the repeat dose
ubchronic toxicity study, a detailed assessment of the toxic poten-
ials of a standardized extract when administered daily for 90-days
ia oral gavage to Sprague Dawley rats, was carried out.
. Materials and methods
.1. Study design
The 90-day subchronic toxicity study was performed in
ccordance with Organization for Economic Co-operation and
evelopment (OECD) Guidelines for the Testing of Chemicals, No.
08: Repeated Dose 90-day Oral Toxicity Study in Rodents; the U.S.
DA, CDER Guidance for Industry, Botanical Drug Products, June
004; the ICH Harmonized Tripartite Guideline M3  (R2), Current
tep 4 version dated 11 June, 2009; and the WHO  Guidelines for
oxicity Investigation of Herbal Medicines, Research guidelines for
valuating the safety and efﬁcacy of Herbal Medicines, 1993. The
tudy was conducted in compliance with the principles of Good
aboratory Practice as set forth in OECD Series on Principles of Good
aboratory Practice and Compliance Monitoring, Number 1, ‘OECD
rinciples on Good Laboratory Practice’ ENV/MC/CHEM (98) 17 (as
evised in 1997).
.2. Test article
Standardized McB-E60 (extract of a Momordica sp.) used in the
resent study was provided by Nutritional Health Institute Labo-
atories (Tallahassee, FL, USA) and was manufactured at Metaugus,
nc., GA30125, USA as production batch number 9012701 of year
008. The product is a green colored clear liquid.
The product quality was deﬁned by parameters such as ash,
H, protein, dietary ﬁbre, gentisic acid, stigmasterol and totalAnalysis Center, CA for sample # 740-2014-00021037.
sterols. The product had a characteristic odor (a balanced herbal
estery lightly ethanolic smell) and bitter taste. The concentrate was
checked for heavy metals, microbial load and pesticide residues.
The physical characteristics and chemical speciﬁcations of the
product are presented in Table 1.
2.3. Animals
Healthy male and female Sprague-Dawley rats were procured
from Reliance Life Sciences (Navi Mumbai, India) and were acclima-
tized to experimental room conditions for up to six days. Veterinary
examinations were then conducted following which 100 rats (50
males and 50 females) were selected such that the weight variation
within each sex of rats did not exceed ±20% of the mean weight for
that sex (male rats 196.6 g; female rats 160.7 g). The selected rats
were then assigned to control and treatment groups (10/sex/group)
using random numbers generated with MS-Excel. The rats were
group housed with up to two rats of similar sex per cage in steril-
ized solid bottom polypropylene cages with bedding of clean and
sterilized paddy husk. Cages had facilities for food and water bot-
tle, and were suspended on movable stainless steel racks. HVAC
conditions in the experimental animal room were set to maintain
10–15 air changes per hour of 100% fresh and ﬁltered air, condi-
tioned with temperature between 19–25 ◦C and relative humidity
30–70%. The animal room was illuminated for 12 h light on each day
while darkness was maintained for rest of the 12 h. The rats were
fed ad libitum with Nutrilab rodent feed manufactured by Provimi
Animal Nutrition India Pvt. Ltd. (Bangalore, India) and were pro-
vided with potable water ﬁltered through ‘Aquaguard’ water ﬁlter
having built-in ultra violet irradiation process.
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.4. Treatment
Groups of 10 rats per sex were gavaged daily with McB-E60
extract of a Momordica sp.) at dose levels of 0 (Group I- control), 250
Group II- low dose), 500 (Group III- mid  dose), and 1000 (Group IV-
igh dose) mg/kg body weight/day for 90 days. Additional recovery
roups of ﬁve rats per sex were maintained at control (Group V)
nd high dose (Group VI) levels, and were observed for a period
f 28 days after cessation of the 90 days of treatment. This 90-day
tudy was preceded by a 14-day oral toxicity study on McB-E60,
erving as a dose range ﬁnding study in which rats (5/sex/group)
ere administered 0, 100, 300 and 1000 mg/kg bw/day for 14 con-
ecutive days. This 14-day study did not reveal any adverse effects
f McB-E60 extract with respect to parameters such as clinical signs,
ody weight gain, feed intake, necropsy, organ weights and clinical
aboratory investigations. The choice of dose levels for the present
0-day study thus was  made on the basis of history of usage of
omordica charantia as a food by humans, as well as on the basis of
ndings of above 14-day oral toxicity study. The dose of 1000 mg/kg
w/day has been speciﬁed as a ‘limit dose’ by the OECD test guide-
ine. As described in ensuing paragraphs, the rats in this 90-day
ubchronic study were subjected to observations during the 90-day
reatment period as well as during the 28 days of recovery period,
nd, at their termination, were further subjected to evaluations for
rgan weights, laboratory investigations for hematology, urinalysis
nd blood chemistry, and for gross and microscopic pathology.
.5. Parameters investigated
.5.1. Survival, clinical signs, body weight and food consumption
All rats were examined for survival and moribundity twice on
ach working day. All signs of ill health, and any behavioral changes
r reaction to treatment were recorded for individual animals. Cage
ide clinical examinations were conducted daily on all rats while
etailed clinical examinations were conducted weekly during the
0-day treatment period and during the 28-day recovery period.
he detailed observations were made outside the home cage to
ote any changes in skin, fur, eyes, mucous membranes, occur-
ence of secretions and excretions and autonomic activity such as
acrimation, piloerection, pupil size, and unusual respiratory pat-
ern. Any changes in gait, posture and response to handling as
ell as the presence of clonic or tonic movements, stereotypies
r bizarre behavior, were also recorded.
Ophthalmoscopic examination was carried out on all rats prior
o initiation of the experiment and before termination of the treat-
ent period on day 89, on animals from control and high dose
roups. During the 12th week of treatment, all animals were
xamined for assessment of sensory reactivity, assessment of grip
trength and motor activity. These included the functional obser-
ational battery [8]. Individual animal body weights were recorded
rior to commencement of treatment (day of grouping—day 0),
eekly thereafter during the treatment and recovery periods, and
t necropsy (overnight fasted body weights). The quantity of feed
onsumed by rats in each cage was recorded weekly. Feed intake
er rat per day was calculated using the amount of food offered to
ach cage during the period of measurement, and left in each cage
t end of this period, and the number of rats surviving in each cage.
.5.2. Clinical pathology
After completion of 90 days of treatment or the 28 days of recov-
ry period, blood samples were collected from all surviving animals
rom the respective groups in this study. Prior to blood sampling,
nimals were fasted overnight. Sampling of blood was made after
he rats were asphyxiated following inhalation of high (>70%)
oncentration of carbon dioxide. Blood samples were collected sep-
rately in tubes containing anticoagulants EDTA for hematology,ports 3 (2016) 481–489 483
heparin for clinical chemistry and sodium citrate for coagulation
parameters. Smears of freshly obtained blood samples were pre-
pared on glass slides and subjected to staining with Leishman’s
Stain.
2.6. Hematology
The hematological parameters included: Hemoglobin, Packed
cell volume, Total red cell count (RBC), Total white cell count
(WBC), Differential white cell counts (Neutrophils, Lymphocytes,
Eosinophils, Monocytes, Basophils), Platelet count, Reticulo-
cyte count, Absolute RBC indices (Mean corpuscular volume-
MCV, Mean corpuscular hemoglobin- MCH, Mean corpuscu-
lar hemoglobin concentration—MCHC). Coagulation Parameters
included Prothrombin Time and Activated Partial Thromboplastin
Time. The hematological estimations were performed using ‘Abbott
Cell Dyn 3700′ Hematology Analyser and ‘Semi- Automated Coag-
ulation Analyser Start® 4 (Diagnostica Stago, France).
2.7. Clinical chemistry
Clinical chemistry parameters included: Sodium, Potassium,
Glucose, Total Cholesterol, Urea nitrogen (BUN), Urea, Creatinine,
Protein (total), Albumin, Globulin, Total Protein, Albumin/Globulin
(A/G) Ratio, Alanine aminotransferase (ALT), Aspartate amino-
transferase (AST), Alkaline phosphatase (ALP), Gamma  glutamyl
transpeptidase (GGT), Bilirubin total, Calcium, Phosphorus and
Triglycerides. Plasma samples were analysed individually (not
pooled) for determination of clinical chemistry parameters using
Synchron CX-5 Pro Fully Automatic Random Access Analyser (Beck-
man  Coulter, Inc.), except that the Calcium determination was
performed using Dimension X-pand Plus Clinical Chemistry Sys-
tem (Siemens Healthcare Diagnostics Inc.). Sodium and Potassium
determinations were made using Easylyte Analyser (Medica Cor-
poration, MA,  USA).
2.8. Urinalysis
Urinalysis was performed in last week of the study, on day 88,
before termination of the treatment period. Initially urinalysis was
performed on animals from control (Group I) and high dose groups
(Group IV). Urine samples were collected using a battery of specially
designed stainless steel urine collection cages. Each rat was housed
in this cage. Urine samples were collected over a period of about
4 h. Urinalysis parameters included Colour, Appearance, Speciﬁc
gravity, pH, Protein, Glucose, Ketone, Volume (timed), Bilirubin,
Urobilinogen, Nitrite, Leucocyte, Occult blood, and Microscopy.
Tests were performed using Multistix® 10 SG multiple reagent
diagnostic strips manufactured by Siemens Healthcare Diagnos-
tics and were read using “Clinitek Status” Urine Analyser’ (Siemens
Medical Solutions Diagnostics).
2.8.1. Necropsy and pathology
2.8.1.1. Terminal necropsy and tissue collection. On completion of
90 days of treatment or the 28-day recovery periods, all rats were
euthanized by exsanguination, preceded by their asphyxiation by
inhalation of high (>70%) concentration of carbon dioxide for a brief
period. The rats were subjected to a complete gross necropsy which
included examination of external surfaces, oriﬁces, cranial, tho-
racic and abdominal cavities and all organs. At terminal necropsy,
organs viz. kidney (right and left), liver, heart, adrenal glands (right
and left), spleen, brain, testes (right and left), uterus, thymus, epi-
didymides (right and left), ovaries (right and left), from all surviving
animals were carefully dissected and trimmed to remove fat and
other contiguous tissue, and then were weighed immediately to
minimize the effects of drying on organ weight. Values of these
484 N.S. Deshmukh / Toxicology Reports 3 (2016) 481–489
Fig. 1. Body weights of male rats treated with McB-E60 (extract of a Momordica sp.). Mean body weights for male rats during the treatment period of 90 days and the 28-day
recovery period. The values are presented as means ± standard deviation.
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tig. 2. Body weights of female rats treated with McB-E60 (extract of a Momordica 
8-day recovery period. The values are presented as means ± standard deviation.
rgans as percent of necropsy body weights were calculated (rel-
tive organ weights). In addition to these organs collected for
easurements, all the tissues (total over 35) were collected and
reserved in 10% neutral buffered formalin. In addition, samples of
ny macroscopically abnormal tissues were preserved, along with
amples of adjacent normal tissue where appropriate.
.9. Histopathological examination
Tissues and organs mentioned above and any other tissues
ith gross lesions were ﬁxed in 10% neutral buffered formalin
lungs were inﬂated with ﬁxative prior to immersion), embedded
n parafﬁn wax, sectioned at about 5 m thickness and stained with
ematoxylin and eosin, for microscopic examination. Microscopic
xaminations were carried out on all listed organs and tissues of
ll surviving animals of Group I (control) and Group IV (high dose),
acriﬁced at termination of the treatment period. Since treatment
elated adverse effects were not observed in any tissues/organs at
he high dose level, the investigations were not extended to the lowean body weights for female rats during the treatment period of 90 days and the
dose (Group II), mid dose (Group III) and to the recovery groups.
The microscopic ﬁndings were allocated grades of severity using a
convention adopted at the test facility.
2.10. Statistical analysis
Statistical analysis was performed using IBM SPSS Statistical
Software (version 23). The body weight, food consumption, hema-
tology, clinical chemistry, organ weight and some neurological
examination data, of different groups were subjected to one-way
analysis of variance (ANOVA) after assessing their homogeneity
by Levene’s test. Dunnett’s test was employed as a post-hoc test
wherever necessary. Comparisons of data from two groups such as
those of body weights, food intake, hematology, clinical chemistry
and organ weight data of recovery groups, and urinalysis parame-
ters (control and high dose groups) were performed by employing
Independent t test. The variance was  evaluated at 5% level of sig-
niﬁcance.
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Table  2
Hematological parameters of male rats treated with McB-E60 (extract of a Momordica sp.) (on study day 91).
Parameter Units mg/kg/day
(G-I) (G-II) (G-III) (G-IV)
0 100 500 1000
RBC ×106 L 8.71 ± 0.30 8.80 ± 0.52 8.77 ± 0.46 8.67 ± 0.63
Hb  g/dL 15.12 ± 0.53 15.27 ± 0.80 15.16 ± 0.70 14.98 ± 1.01
PCV  % 43.19 ± 1.63 43.29 ± 1.91 42.81 ± 1.76 42.50 ± 2.62
MCH  pg 17.37 ± 0.36 17.37 ± 0.39 17.30 ± 0.36 17.29 ± 0.47
MCV  ﬂ 49.62 ± 1.08 49.27 ± 1.58 48.87 ± 1.02 49.09 ± 1.97
MCHC g/dL 35.01 ± 0.53 35.27 ± 0.74 35.41 ± 0.42 35.24 ± 0.59
PLT  ×103 L 939.20 ± 104.08 924.60 ± 88.45 892.60 ± 71.52 901.10 ± 81.24
WBC  ×103 L 7.21 ± 1.51 7.14 ± 1.36 6.47 ± 0.53 6.70 ± 1.74
RET  % 2.86 ± 1.89 2.51 ± 0.53 2.30 ± 0.33 2.28 ± 0.52
NEU  % 25.90 ± 6.01 23.46 ± 3.85 28.07 ± 6.01 25.78 ± 6.21
LYM  % 71.84 ± 5.98 74.21 ± 3.90 68.45 ± 6.63 71.07 ± 8.54
MON  % 0.683 ± 0.432 0.805 ± 0.495 1.597 ± 2.175 1.459 ± 2.833
EOS  % 1.573 ± 0.336 1.522 ± 0.529 1.833 ± 0.599 1.582 ± 0.393
BAS  % 0.000 ± 0.000 0.006 ± 0.014 0.029 ± 0.070 0.092 ± 0.274
General  blood picture NAD NAD NAD NAD
Coagulation Values
PT sec 17.01 ± 3.21 16.60 ± 1.35 15.93 ± 1.29 16.25 ± 1.33
APTT  sec 12.03 ± 1.05 12.69 ± 1.81 12.89 ± 1.47 13.19 ± 2.05
Values are mean ±SD for 10 rats in each group. RBC = red blood cell count; Hb = hemoglobin; WBC  = white blood cell count; MCV  = mean corpuscular volume; MCH  = mean
corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; PLT = platelet count; RET = reticulocyte count; NEU = neutrophil; LYM = lymphocyte;
MON  = monocyte; EOS = e eosinophil; BAS = basophil; PT = prothrombin time; APTT = activated partial prothrombin time.
Table  3
Hematological parameters of female rats treated with McB-E60 (extract of a Momordica sp.) (on study day 91).
Parameter Units mg/kg/day
(G-I) (G-II) (G-III) (G-IV)
0 100 500 1000
RBC ×106 L 8.10 ± 0.69 8.51 ± 0.48 8.46 ± 0.31 8.36 ± 0.28
Hb  g/dL 14.81 ± 1.05 15.32 ± 0.70 15.39 ± 0.54 15.22 ± 0.65
MCH  pg 18.31 ± 0.59 18.01 ± 0.38 18.20 ± 0.55 18.20 ± 0.40
MCV  ﬂ 51.17 ± 2.21 50.96 ± 1.25 51.01 ± 1.57 51.37 ± 0.96
MCHC g/dL 35.80 ± 0.98 35.34 ± 0.41 35.68 ± 0.71 35.44 ± 0.87
PCV  % 41.37 ± 2.77 43.34 ± 1.72 43.13 ± 0.99 42.94 ± 1.39
PLT  ×103 L 929.80 ± 51.59 941.50 ± 96.09 851.80 ± 62.63 872.60 ± 85.06
WBC  ×103 L 6.13 ± 1.11 5.73 ± 0.76 6.43 ± 1.31 6.46 ± 0.82
RET  % 4.18 ± 5.49 3.57 ± 2.10 3.15 ± 0.74 2.90 ± 0.60
NEU  % 27.47 ± 5.46 24.92 ± 3.11 27.46 ± 3.86 27.55 ± 5.26
LYM  % 68.42 ± 6.18 69.55 ± 6.56 67.96 ± 4.03 68.16 ± 5.89
MON  % 1.553 ± 1.946 3.040 ± 4.536 1.261 ± 2.075 1.563 ± 2.485
EOS  % 2.549 ± 0.931 2.488 ± 0.703 3.284 ± 1.201 2.685 ± 0.794
BAS  % 0.097 ± 0.286 0.021 ± 0.041 0.026 ± 0.082 0.034 ± 0.108
General  blood picture NAD NAD NAD NAD
Coagulation Values
PT sec 15.90 ± 1.19 16.76 ± 1.26 16.10 ± 0.88 16.13 ± 1.18
APTT  sec 13.57 ± 1.26 15.76 ± 8.01 12.76 ± 1.71 13.09 ± 1.06
V moglo
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aalues are mean ±SD for 10 rats in each group. RBC = red blood cell count; Hb = he
orpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration;
ON  = monocyte; EOS = e eosinophil; BAS = basophil; PT = prothrombin time; APTT =
. Results
.1. Survival, clinical observations, ophthalmological
xamination
The daily oral administration of McB-E60 (extract of a Momordica
p.) for 90 consecutive days at doses up to 1000 mg/kg bw/day
id not cause any adverse effect on the survival of the male and
emale rats in this study. There was no incidence of any mortality
mongst the treated male and female rats. The daily general clin-
cal examinations and the weekly detailed clinical examinations
f rats conducted during the treatment and recovery periods did
ot reveal any remarkable and abnormal clinical signs indicative of
ystemic toxicity (data not shown), in rats of either sex, following
dministration of McB-E60 (extract of a Momordica sp.) at doses upbin; WBC  = white blood cell count; MCV  = mean corpuscular volume; MCH  = mean
 platelet count; RET = reticulocyte count; NEU = neutrophil; LYM = lymphocyte;
ated partial prothrombin time.
to 1000 mg/kg bw/day. The ﬁndings from neurological evaluations
following treatment of male and female rats with McB-E60 (extract
of a Momordica sp.) at doses up to 1000 mg/kg bw/day did not reveal
any remarkable and abnormal alterations in qualitative and quan-
titative parameters of their sensory reactivity, grip strength and
motor activity, as was evident during assessment of the ‘functional
observational battery’ carried out during 12th week of the study
(data not shown). The values of quantitative parameters (frequen-
cies of urination, defecation and rearing, the landing foot splay and
the grip strength) of the treatment group rats of both sex did not
differ signiﬁcantly (P > 0.05) from those of the vehicle control group
rats during the 12th week of the study. Ophthalmoscopy prior to
study initiation and near experimental completion (Day 85) did not
reveal any abnormalities.
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Table 4
Clinical chemistry parameters of male rats treated with McB-E60 (extract of a Momordica sp.) (on study day 91).
Parameter Units mg/kg/day
(G-I) (G-II) (G-III) (G-IV)
0 250 500 1000
AST U/L 153.20 ± 24.78 120.80a ± 23.50 130.50 ± 12.72 138.20 ± 29.50
ALT  U/L 117.10 ± 33.69 110.10 ± 30.82 109.40 ± 11.86 114.60 ± 26.62
ALP  U/L 112.90 ± 15.81 113.60 ± 12.53 124.30 ± 19.87 111.40 ± 9.99
TBILI  U/L 0.27 ± 0.18 0.22 ± 0.19 0.29 ± 0.20 0.26 ± 0.21
A/G  ratio g/dL 0.20 ± 0.01 0.20 ± 0.01 0.20 ± 0.01 0.20 ± 0.02
BUN  mg/dL 17.50 ± 1.78 16.80 ± 2.35 17.20 ± 1.81 17.60 ± 3.57
UREA mg/dL 25.20 ± 2.56 24.19 ± 3.38 24.77 ± 2.61 25.34 ± 5.13
CHOL  mg/dL 119.30 ± 15.04 118.00 ± 6.43 113.10 ± 16.16 118.60 ± 16.05
TG  mg/dL 36.80 ± 9.96 44.20 ± 13.51 37.10 ± 11.80 46.00 ± 9.46
GLUC  mg/dL 115.10 ± 24.22 112.10 ± 9.93 108.00 ± 11.26 117.00 ± 11.51
TP  g/dL 6.59 ± 0.32 6.67 ± 0.24 6.51 ± 0.32 6.65 ± 0.47
ALB  g/dL 1.11 ± 0.07 1.11 ± 0.07 1.10 ± 0.08 1.09 ± 0.09
PHO  mg/dL 7.51 ± 1.00 7.36 ± 0.60 6.83 ± 0.54 7.10 ± 0.65
CREA  mg/dL 0.55 ± 0.08 0.53 ± 0.07 0.53 ± 0.05 0.53 ± 0.07
GGT  U/L 5.70 ± 1.16 6.00 ± 0.94 5.40 ± 1.26 5.80 ± 0.63
GLOB  g/dL 5.48 ± 0.26 5.56 ± 0.20 5.41 ± 0.26 5.56 ± 0.42
Na  mmol/L 145.48 ± 1.41 146.59 ± 1.51 145.57 ± 1.60 145.35 ± 1.54
K  mmol/L 4.64 ± 0.56 4.48 ± 0.36 4.42 ± 0.29 4.77 ± 0.45
Ca  mmol/L 10.12 ± 0.40 10.10 ± 0.28 9.69 ± 0.63 9.90 ± 0.32
Values are mean ±SD for 10 rats in each group. Aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), total bilirubin (TBILI), urea nitrogen (BUN), blood
creatinine (CREA), total cholesterol (CHOL), triglycerides (TG), fasting glucose (GLUC), total serum protein (TP), albumin (ALB), globulin (GLOB), calcium (Ca), inorganic
phosphorus (PHO), sodium (Na), potassium (K); a = Group mean value signiﬁcantly lower (P < 0.05) than the respective value of the vehicle control group
Table  5
Clinical chemistry parameters of female rats treated with McB-E60 (extract of a Momordica sp.) (on study day 91).
Parameter Units mg/kg/day
(G-I) (G-II) (G-III) (G-IV)
0 250 500 1000
AST U/L 118.30 ± 26.41 105.20 ± 11.85 113.40 ± 14.70 112.20 ± 10.35
ALT  U/L 90.10 ± 26.39 76.50 ± 12.35 85.40 ± 14.03 92.10 ± 20.42
ALP  U/L 83.60 ± 18.11 94.60 ± 28.00 108.80 ± 22.74 107.90 ± 25.81
TBILI  U/L 0.10 ± 0.00 0.11 ± 0.03 0.10 ± 0.00 0.10 ± 0.00
A/G  ratio g/dL 0.20 ± 0.01 0.20 ± 0.01 0.20 ± 0.01 0.20 ± 0.01
BUN  mg/dL 19.80 ± 2.78 18.10 ± 1.52 18.50 ± 2.95 20.50 ± 2.95
UREA  mg/dL 28.51 ± 4.00 26.06 ± 2.19 26.64 ± 4.25 29.52 ± 4.25
CHOL  mg/dL 146.50 ± 20.78 142.70 ± 14.37 145.10 ± 17.67 157.60 ± 15.49
TG  mg/dL 31.70 ± 6.25 37.50 ± 7.98 34.40 ± 11.20 29.70 ± 3.13
GLUC  mg/dL 105.40 ± 14.49 105.00 ± 8.83 101.90 ± 4.68 106.70 ± 7.42
TP  g/dL 6.58 ± 0.34 6.56 ± 0.35 6.58 ± 0.21 6.54 ± 0.08
ALB  g/dL 1.11 ± 0.06 1.10 ± 0.07 1.10 ± 0.08 1.08 ± 0.04
CREA  mg/dL 0.57 ± 0.09 0.55 ± 0.07 0.57 ± 0.07 0.62 ± 0.08
GGT  U/dL 5.10 ± 1.52 5.20 ± 1.23 5.30 ± 1.06 5.50 ± 1.51
PHO  mg/dL 5.62 ± 0.71 6.05 ± 0.55 5.97 ± 1.03 5.59 ± 0.84
GLOB  g/dL 5.47 ± 0.31 5.46 ± 0.30 5.48 ± 0.17 5.46 ± 0.10
Na  mmol/L 144.61 ± 0.96 144.18 ± 1.26 143.76 ± 1.37 144.38 ± 1.00
K  mmol/L 4.33 ± 0.29 4.34 ± 0.31 4.29 ± 0.26 4.35 ± 0.39
Ca  mmol/L 10.08 ± 0.34 10.18 ± 0.34 10.05 ± 0.34 10.12 ± 0.16
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.2. Body weights and feed consumption
Daily oral administration of McB-E60 (extract of a Momordica
p.) at doses up to 1000 mg/kg bw/day did not induce any adverse
ffects on the body weight gain by the male and female rats,
uring the treatment period of 90 days and the 28-day recovery
eriod (Figs. 1 and 2). The values of body weights of treated male
nd female rats did not differ signiﬁcantly (P > 0.05) from those
f the vehicle control group rats during the treatment and recov-
ry period. The daily oral administration of McB-E60 (extract of a
omordica sp.) at dose levels up to 1000 mg/kg bw/day did not
nduce any adverse effects on the average daily feed intake by
he male and female rats, during the treatment and recovery peri-
ds. The values of daily feed consumption by the rats, determined alanine aminotransferase (ALT), total bilirubin (TBILI), urea nitrogen (BUN), blood
otal serum protein (TP), albumin (ALB), globulin (GLOB), calcium (Ca), inorganic
 (P < 0.05) than the respective value of the vehicle control group
weekly, were found to be comparable to those of the vehicle con-
trol group rats during the treatment and recovery period. Very
small, biologically insigniﬁcant but statistically signiﬁcant (P < 0.05)
differences, between the values of feed intake were noted during
recovery period (week 17—male rats; week 14—female rats). These
were considered to be incidental.
3.3. Clinical pathology
3.3.1. Hematology
Oral administration of McB-E60 (extract of a Momordica sp.) to
male and female rats for 90 days at dose levels up to 1000 mg/kg
bw/day did not induce any alterations in their hematological
parameters determined at termination of the treatment period
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Table  6
Terminal organ weight in grams of male and female rats treated with McB-E60 (extract of a Momordica sp.) (on study day 91).
Organ Sex (G-I) (G-II) (G-III) (G-IV)
0 mg/kg/day 250 mg/kg/day 500 mg/kg/day 1000 mg/kg/day
Organ weights in grams
Body weight (fasted) M 399.70 ± 21.68 392.90 ± 33.23 385.90 ± 19.52 388.10 ± 21.53
Adrenal  M 0.04 ± 0.00 0.05 ± 0.01 0.04 ± 0.01 0.04 ± 0.01
Brain  M 2.10 ± 0.12 2.16 ± 0.13 2.16 ± 0.17 2.09 ± 0.12
Epididymides M 1.09 ± 0.14 1.11 ± 0.08 1.11 ± 0.06 1.09 ± 0.06
Heart  M 1.50 ± 0.14 1.52 ± 0.22 1.37 ± 0.09 1.43 ± 0.08
Kidney M 3.15 ± 0.30 3.09 ± 0.39 3.05 ± 0.39 3.19 ± 0.35
Liver  M 12.75 ± 1.48 12.05 ± 1.30 12.04 ± 1.31 12.09 ± 1.10
Spleen  M 0.63 ± 0.08 0.65 ± 0.11 0.59 ± 0.09 0.62 ± 0.07
Testes  M 3.01 ± 0.43 3.09 ± 0.14 3.08 ± 0.19 3.35 ± 0.54
Thymus M 0.45 ± 0.10 0.39 ± 0.09 0.41 ± 0.13 0.42 ± 0.08
Body  weight (fasted) F 231.30 ± 11.99 237.70 ± 20.70 241.10 ± 11.07 244.30 ± 16.61
Adrenal  F 0.046 ± 0.005 0.045 ± 0.004 0.048 ± 0.009 0.045 ± 0.007
Brain  F 2.00 ± 0.13 2.01 ± 0.13 2.01 ± 0.05 2.00 ± 0.12
Heart  F 0.98 ± 0.06 1.01 ± 0.08 1.07 ± 0.05 1.03 ± 0.10
Kidney  F 2.16 ± 0.28 2.21 ± 0.27 2.23 ± 0.17 1.98 ± 0.23
Liver  F 7.92 ± 0.74 7.78 ± 0.88 8.28 ± 0.35 7.76 ± 0.91
Ovaries F 0.102 ± 0.023 0.101 ± 0.014 0.102 ± 0.021 0.096 ± 0.022
Spleen F 0.48 ± 0.10 0.45 ± 0.07 0.46 ± 0.04 0.45 ± 0.05
Thymus  F 0.30 ± 0.03 0.33 ± 0.06 0.35 ± 0.06 0.35 ± 0.05
Uterus  and oviducts F 0.47 ± 0.07 0.86 ± 0.60 0.58 ± 0.17 0.64 ± 0.32
Values are mean ±SD for 10 rats in each group.
Table 7
Incidence of histopathological ﬁndings from male rats treated with McB-E60 (extract of a Momordica sp.) (Terminally sacriﬁced—day 91).
Organs Lesion mg/kg/day
(G-I) (G-IV)
0 1000
Stomach (non-glandular) Cyst, keratinized, solitary 1 –
Terminal ileum Hyperplasia, lymphoid, sub-mucosal, minimal 1 –
Heart  Lymphocytic inﬁltration, minimal 1 –
Trachea Inﬁltration, lymphoytic, sub-mucosal, minimal 3 3
Colon Hyperplasia, lymphoid, sub-mucosal, minimal 2 –
Kidney Dilatation, tubular, minimal 7 6
Cyst,  hyaline 1 1
Regeneration, tubular, minimal 1 –
Inﬁltration, lymphocytic, minimal 4 3
Lungs  Perivascular aggregation, lymphocytic, minimal to mild 4 2
Peribronchial lymphoid tissue hyperplasia, mild 4 3
Alveolar macrophages, minimal 2 –
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Pituitary Gland Cysts, pars distalis 
Prostate Inﬁltration, neutrophilic, mild 
day-91) and at end of the 28-day recovery period (day-119)
Tables 2 and 3). The values of all hematological parameters eval-
ated in this study of rats treated with McB-E60 (extract of a
omordica sp.) did not differ signiﬁcantly from those of the respec-
ive vehicle control group values (P > 0.05) on days 90 and 119.
lthough the group mean values of % monocytes and % basophils
n male rats exhibited a dose dependent increase, the values were
ell within the historical control ranges relative to the sex, strain
nd species of the animals tested. The differences were also sta-
istically insigniﬁcant, and hence considered as incidental or of no
oxicological signiﬁcance. The microscopic examination of stained
lood smears did not reveal any abnormal and immature cells.
.3.2. Clinical chemistry
Oral administration of McB-E60 (extract of a Momordica sp.) to
ale and female rats at dose levels of 250, 500, and 1000 mg/kg
w/day (Groups II, III and IV, respectively) for 90 days did not
nduce any alterations in their clinical chemistry parameters
Tables 4 and 5) at termination of the treatment period (day 91),
nd on day 119, at end of the 28-day recovery period., minimal – 1
1 –
– 1
Although, a slight but statistically signiﬁcant (P < 0.05) decrease
in the levels of AST in Group II (low dose) male rats as compared to
control group (Group I) was  noted, it was considered to be an inci-
dental ﬁnding with no toxicological signiﬁcance. This was since this
observed value of AST (120.8 IU/L) was  well within the historical
control range relative to the sex, strain and species of the animals
tested, and also since there was  an absence of any alterations in
gross pathology, organ weights and other clinical chemistry param-
eters associated with liver in this group. Similarly a slight but
statistically signiﬁcant ‘lower than control’ group mean value of
Calcium in Group IV(R) female rats observed at end of the 28-day
recovery period (9.76 ± 0.26 mg/dL) was found to be of no biolog-
ical signiﬁcance due to its comparability to the historical control
range of 9.8–11.7 mg/dL relative to the sex, strain and species of
the animals tested.3.3.3. Urinalysis
There were no treatment-related adverse effects in urinalysis
parameters, including altered microscopic appearance of the cen-
trifuged deposits, when examined prior to end of the treatment
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Table 8
Incidence of histopathological ﬁndings from female rats treated with McB-E60
(extract of a Momordica sp.) (Terminally sacriﬁced—day 91).
Organs Lesion mg/kg/day
(G-I) (G-IV)
0 1000
Trachea Inﬁltration, lymphoytic, sub-mucosal, minimal 3 2
Colon Hyperplasia, lymphoid, sub-mucosal, minimal 2 1
Kidney Dilatation, tubular, minimal 4 3
Inﬁltration, lymphocytic, minimal 1 –
Lungs Perivascular aggregation, lymphocytic, minimal to mild 2 3
Peribronchial lymphoid tissue hyperplasia, mild 3 2
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pAlveolar macrophages, minimal 1 –
Rectum Hyperplasia, lymphoid, sub-mucosal, minimal – 1
Esophagus Acanthosis and hyperkeratosis, minimal – 1
eriod, on day 88, in male and female rats (data not shown) fol-
owing administration of McB-E60 (extract of a Momordica sp.) at
ose level of 1000 mg/kg bw/day. The observations recorded for
ualitative urine parameters viz. color, appearance, and graded
uantities of analytes such as protein, glucose, ketones, occult blood
nd bilirubin were found to be comparable between the high dose
roup rats (Group IV) treated with McB-E60 (extract of a Momordica
p.) and the vehicle control group (Group I) of rats. Group mean
alues of speciﬁc gravity, urobilinogen and pH of urine of male
nd female rats treated with the extract did not differ signiﬁcantly
P > 0.05) from those of the vehicle control group rats as evident on
he 88 day of treatment.
.4. Organ weights
The absolute organ weights of different groups following treat-
ent with McB-E60 (extract of a Momordica sp.) at dose levels of
50, 500, and 1000 mg/kg bw/day for 90-days are summarized in
able 6. No toxicologically or statistically signiﬁcant changes in
rgan weights were observed in absolute (Table 6) and relative
rgan weights (data not shown) when compared to the vehicle
ontrol group.
.5. Necropsy and microscopic ﬁndings
There were no treatment-related and remarkable gross abnor-
alities in the organs/tissues of rats in any of the groups as
videnced during the gross necropsy performed at termination of
he 90 days of treatment or of the 28 days of recovery period. The
ncidence and severity of histopathological ﬁndings from vehicle
ontrol group (Group I) and the high dose group (Group IV) fol-
owing treatment with McB-E60 (extract of a Momordica sp.) at
ose levels of 0 and 1000 mg/kg bw/day, respectively for male
nd female rats are summarized in Tables 7 and 8. However, as
escribed below few instances of microscopic ﬁndings (incidence
ooled for sexes) noted were considered to be unrelated to treat-
ent with McB-E60 (extract of a Momordica sp.) due to their small
ncidence with minimal severity, and to the comparability of their
ncidence within the vehicle control and the McB-E60 treated
roup, for both sexes.
Such isolated histological instances included: in kidneys a min-
mal tubular dilatation (11/20 in Group I and 9/20 in Group IV),
inimal inﬁltration with lymphocytes (5/20 in Group I and 3/20
n Group IV), isolated incidence of hyaline cyst in males only (1/10
n Group I and 1/10 in Group IV) and an isolated observation of
inimal focal tubular regeneration in male rats only; in lungs a
inimal to mild perivascular aggregation of lymphocytes (6/20 in
roup I and 5/20 in Group IV), mild peribronchial lymphoid tissue
yperplasia (7/20 in Group I and 5/20 in Group IV), and minimal
resence of alveolar macrophages (3/20 in Group I); in trachea aports 3 (2016) 481–489
minimal sub mucosal inﬁltration of lymphocytes (6/20 in Group
I and 5/20 in Group IV); in intestines isolated instances of mini-
mal  sub-mucosal lymphoid hyperplasia in terminal ileum (1/20 in
Group I), colon (4/20 in Group I and 1/20 in Group IV) and in rectum
(2/20 in Group IV).
In addition to above described ﬁndings, there were isolated
ﬁndings of minimal acanthosis and hyperkeratosis in oesopha-
gus (Group IV—female); cysts in pars distalis of pituitary (Group
I—male); mild neutrophilic inﬁltration in prostate (Group IV);
keratanized cyst in non-glandular stomach (Group I—male) and
minimal lymphocytic inﬁltration in heart (Group I—male).
All the above listed ﬁndings are expected background lesions
commonly observed in conventionally housed rats of this age. These
limited ﬁndings were considered incidental and toxicologically
irrelevant as there were no convincing incidence patterns/trends
to suggest a relationship to administration of test article McB-E60
(extract of a Momordica sp.).
4. Discussion
The results of present repeat-dose animal toxicity study
show that oral (gavage) administration of McB-E60 (extract of a
Momordica sp.) to male and female rats, daily for 90 consecu-
tive days by oral gavage, and at the dose levels of 250, 500 and
1000 mg/kg/day, resulted in no incidence of mortality, no inci-
dence of any abnormal clinical signs (including neurotoxicity) in
the male and female rats, no effects on the body weights/body
weight gain, no effect on the feed consumption, no effects on
the hematological parameters, no effects on the blood chemistry
and urinalysis parameters, no alterations in the absolute and rel-
ative organ weights, and no remarkable gross pathological and
histopathological alterations suggestive of systemic toxicity. For all
measured parameters the values for both the controls and the unaf-
fected treatment groups were within the range of historical control
values relative to the sex, strain and species of the animals tested.
In general, treatment of the animals with McB-E60 (extract of a
Momordica sp.) at doses up to 1000 mg/kg bw/day was  well toler-
ated.
In the present subchronic study, a signiﬁcant decrease in the
levels of AST in low dose group male rats treated McB-E60 (extract
of a Momordica sp.) was  noted as compared with respective con-
trols group. The biologically insigniﬁcant decrease in AST value
(120.8 IU/L) was well within the historical control range and was
not considered to be treatment related, also since there was
an absence of any adverse alterations in gross and microscopic
appearance, organ weights and other clinical chemistry parame-
ters associated with liver in this group. Additionally, some limited
histopathological ﬁndings were noted in kidney, lungs, trachea and
intestine (Tables 7 and 8). However, there were no convincing inci-
dence patterns/trends to suggest a relationship to treatment with
McB-E60 (extract of a Momordica sp.). These ﬁndings are known
to be expected background lesions commonly observed in conven-
tionally housed rats of this age, and hence were considered to be
incidental and toxicologically irrelevant.
None of the above described changes following administra-
tion of the McB-E60 (extract of a Momordica sp.) were considered
adverse as the changes were minor (within historical control values
of the test facility), occurred in only one sex, were not dose-related,
non-adverse and/or inconsistent, were not supported by any other
changes in related clinical parameters or histopathological obser-
vations.M. charantia or bitter melon is the plant that has received the
most attention for its anti-diabetic properties. The available infor-
mation from published studies suggests blood-glucose-lowering
effect of bitter gourd when fed orally [7]. The juice formulations
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effects on arterial thickness and stiffness in obese youth, J. Clin. Endocrinol.
Metab. (2014), http://dx.doi.org/10.1210/jc.2013-3519.
[14] K.S. Zanker, B. Mang, M. Wolters, A. Hahn, Personalized diabetes and cancer
medicine: a rationale for anti-diabetic nutrition (bitter melon) in a supportiveN.S. Deshmukh / Toxicolo
f bitter gourd have proven to be more effective in lowering blood
ugar and HbA1c levels than its dried fruit products. In addition to
resh fruit extracts, the glucose lowering effects were also found
n ethanolic plant extracts. Biochemical and animal model exper-
ments have produced abundant data and hypotheses accounting
or the anti-diabetic effects of M.  charantia. In recent years, several
tudies have focused on the glucose-lowering effects of bitter gourd
omponents. In these studies, hypoglycemic activity could not be
emonstrated in normoglycemic animals [12]. The ﬁndings from
he present study also suggest that M.  charantia is unlikely to cause
ypoglycemic activity in normoglycemic animals as treatment of
he male and female rats with McB-E60 (extract of a Momordica
p.) at doses up to 1000 mg/kg bw/day for 90 consecutive days by
ral gavage did not affect blood glucose levels.
The ﬁndings from this study, designed as per OECD guide-
ines, suggest that oral administration of McB-E60 (extract of a
omordica sp.) at levels up to 1000 mg/kg bw/day does not cause
ny adverse or otherwise effects in male and female rats. Based
n the results of this study, the no-observed effect level (NOEL)
f McB-E60 (extract of a Momordica sp.) was found to be greater
han 1000 mg/kg bw/day, the highest dose tested. A standardized,
ncapsulated extract dosage of McB-E60 (extract of a Momordica
p.) ranges from 100 to 200 mg  three times daily (up to 600 mg/day).
he NOEL for McB-E60 (extract of a Momordica sp.) from the present
tudy provides approximately 100-fold safety factor over the rec-
mmended dose of 10 mg/kg/day. Therefore, from the results of the
tudy presented herein, it may  be concluded that the use of appro-
riate levels of the McB-E60 (extract of a Momordica sp.) as a dietary
upplement is considered safe.eferences
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